Invention Grant
- Patent Title: Use of macimorelin in assessing growth hormone deficiency in children
-
Application No.: US17375709Application Date: 2021-07-14
-
Publication No.: US11644474B2Publication Date: 2023-05-09
- Inventor: Nicola Ammer , Michael Teifel , Beate Aue
- Applicant: Æterna Zentaris GmbH
- Applicant Address: US SC Charleston
- Assignee: ÆTERNA ZENTARIS GMBH
- Current Assignee: ÆTERNA ZENTARIS GMBH
- Current Assignee Address: DE Frankfurt am Main
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: G01N33/74
- IPC: G01N33/74 ; A61K38/27 ; G01N33/49

Abstract:
The present invention provides a method for measuring growth hormone level in a human child, including a method of assessing pituitary-related growth hormone deficiency in a human child as a stand-alone test. The method includes the steps of oral administration of an effective amount of macimorelin to the child, collecting from the child two or three post-administration blood samples within a range of about 60 minutes after administration, and determining the level of growth hormone in the samples. The method can be used for diagnosing pituitary-related growth hormone deficiency in a child when the peak level of determined growth hormone in the samples is below a cut-off value.
Public/Granted literature
- US20220026449A1 USE OF MACIMORELIN IN ASSESSING GROWTH HORMONE DEFICIENCY IN CHILDREN Public/Granted day:2022-01-27
Information query
IPC分类: